Steven Idell

I began as a founder and effectively serving as Chief Scientific Officer at the inception of the company, which was incorporated as of this date, as noted in my 2015 disclosure. All research activities remain as listed for the 2015 disclosure with the addition of the following newly acquired grants: 1) R21ES025815-01A1 Role Of P53 And PAI-1-1 In Tobacco Smoke -Exposure Induced Lung Injury. Shetty S. (PI), Idell S, CO-I. 2) R01HL133067-01 Control Of Fibrosing Lung Disease By P53-Mir-34a-Targeted Therapeutics Shetty S, PI, Idell S Co-I. 3) R01HL130133-01A1 Fibrinolytic Proteases, meso-mesenchymal transition and pleural remodeling. Tucker (PI) Idell S (Co-I) 4)1U54ES027698-01 Fibrinolytic Therapies For Methyl Isocyanate (White C, PI) Idell S, Site PI. 5)1R01HL130402-01A1 Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema MPI: Florova, G; Idell, S; Komissarov, A. 6) Phase 1a/1b Trial of LTI-01 (Single Chain Urokinase, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions or Empyema PROTOCOLNUMBER: LTI01-1001. LTI. SI, Medical Liaison. No changes from 2015 disclosure information.